Want to see DE:B8FK full AI Analyst Report?
B8FK Stock Chart & Stats
€2.53
€0.02(0.90%)
At close: 4:00 PM EST
€2.53
€0.02(0.90%)
Day’s Range― - ―
52-Week Range€2.21 - €5.10
Previous CloseN/A
Volume104.00
Average Volume (3M)2.00K
Market Cap
€21.27M
Enterprise Value€11.99
Total Cash (Recent Filing)€3.08M
Total Debt (Recent Filing)€1.15M
Price to Earnings (P/E)―
Beta0.11
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding6,076,862
10 Day Avg. Volume5,352
30 Day Avg. Volume2,005
Financial Highlights & Ratios
PEG Ratio0.39
Price to Book (P/B)0.99
Price to Sales (P/S)1.12
P/FCF Ratio-3.33
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Gross MarginAn approximately 83% gross margin indicates the products retain substantial economics after direct costs. If maintained, this margin can provide a foundation for funding commercial activity and eventually converting prescription demand into operating profitability despite current losses.
Conservative LeverageVery low leverage limits interest burden and reduces dependence on creditors, giving Biofrontera greater flexibility as it addresses operating losses. A conservative capital structure can also improve resilience and preserve strategic options if the business requires time to restore profitability.
Recurring PDT ConsumablesThe combination of PDT equipment and recurring topical gel consumption gives Biofrontera a repeat-use business model rather than relying solely on one-time device sales. Greater clinician adoption and procedure volumes could therefore support more durable revenue generation over time.
Bears Say
Persistent Cash BurnOngoing negative operating and free cash flow means the core business is consuming cash rather than funding itself. Continued burn can increase reliance on external financing, constrain investment in growth, and raise the risk that additional capital is needed before profitability is reached.
Volatile Revenue And LossesThe sharp revenue contraction after 2023 and limited recovery indicate inconsistent commercial performance. Combined with a continuing net loss, this weakens earnings visibility and makes it harder for the company to leverage its high gross margin into dependable operating and shareholder returns.
Shrinking Equity BaseThe substantial reduction in equity suggests that accumulated losses or other reductions have materially weakened the capital base. Negative ROE shows the remaining shareholder capital is not currently generating returns, limiting financial resilience even though debt levels remain low.
Biofrontera News
B8FK FAQ
What was Biofrontera AG’s price range in the past 12 months?
Biofrontera AG lowest stock price was €2.21 and its highest was €5.10 in the past 12 months.
What is Biofrontera AG’s market cap?
Biofrontera AG’s market cap is €21.27M.
When is Biofrontera AG’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Biofrontera AG’s earnings last quarter?
Currently, no data Available
Is Biofrontera AG overvalued?
According to Wall Street analysts Biofrontera AG’s price is currently Overvalued.
Does Biofrontera AG pay dividends?
Biofrontera AG does not currently pay dividends.
What is Biofrontera AG’s EPS estimate?
Biofrontera AG’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Biofrontera AG have?
Biofrontera AG has 6,076,862 shares outstanding.
What happened to Biofrontera AG’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Biofrontera AG?
Currently, no hedge funds are holding shares in DE:B8FK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Biofrontera Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-75.58%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-20.27%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Biofrontera AG
Biofrontera AG operates as a biopharmaceutical company specializing in dermatology. It conducts research, development, and commercialization of skin-related products across Germany, Spain, the United Kingdom, the broader European continent, the United States, and other global markets. Its primary products include Ameluz and the BF-RhodoLED lamp, which are utilized for treating mild to moderate actinic keratoses on the face and scalp, addressing field cancerization, and managing fatal squamous cell carcinoma. The company also supplies the RhodoLED XL lamp, engineered for treating multiple interspersed lesions, alongside Belixos, a cosmetic range developed for irritated and sensitive skin. Biofrontera AG maintains a licensing and supply agreement with Maruho Co., Ltd. Founded in 1997, the company's corporate headquarters are situated in Leverkusen, Germany.
Technical Analysis
Eckert & Ziegler Strahlen und Medizintechnik
―
Evotec
―
Merck KGaA
―
Heidelberg Pharma AG
―
Dermapharm Holding SE
―